COPD Expert Opinions
In this section
Eric Bateman
What Differentiates COPD Exacerbations From Asthma Exacerbations?
Join global expert Dr. Eric Bateman to gain insight into how to distinguish between exacerbations in patients with COPD and asthma. In this video, you’ll gain insight into the distinct characteristics of exacerbations in patients with COPD.
Meet the expert
Eric Bateman
Eric Bateman, MD, MBChB, FRCS, DCH, FERS, is Emeritus Professor of Medicine at the University of Cape Town (UCT) in South Africa. He is the Founder and former Director of the UCT Lung Institute and Head of the Division of Pulmonology in the Department of Medicine at UCT and Groote Schuur Hospital. He is a fellow of the Royal College of Physicians, an elected Fellow of UCT, a Founding Fellow of the European Respiratory Society, an honorary life Fellow of the South African Thoracic Society, and an A-rated researcher (National Research Foundation of South Africa). Professor Bateman’s research interests include the pharmacology and management of asthma and community-based interventions to improve the care of patients with chronic respiratory diseases.
Disclosures:
Professor Bateman has received lecture fees from ALK, AstraZeneca, Chiesi USA, Menarini, Novartis, Orion, Regeneron, and Sanofi and consultancy or advisory board fees from ALK, AstraZeneca, Novartis, Regeneron, and Sanofi. Member of the board and science committee for the Global Asthma Initiative for Asthma (GINA).
Ian Pavord
The Heterogeneity of Underlying Inflammation in Patients With COPD
Join global expert Prof. Ian Pavord as he discusses the heterogeneity of underlying inflammation in patients with COPD and provides insights on effectively communicating this complexity to non-specialists.
Meet the expert
Ian Pavord
Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci, is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He was an inaugural Fellow of ERS in 2014 and became a Fellow of the Academy of Medical Science in 2015. Prof. Pavord has a research interest in the clinical aspects of inflammatory airway diseases and has pioneered the use of non-invasive measures of airway inflammation. He has identified several clinically important phenotypes of inflammatory airway disease, discovered clinically important biomarkers, and played a lead role in the clinical development of 3 treatments for severe airway disease.
Disclosures:
Professor Pavord has received honoraria for speaking at sponsored meetings from Aerocrine, AstraZeneca, Almirall, Boehringer Inglehiem, Chiesi, GlaxoSmithKline, Novartis, Menarini, Sanofi and Regeneron, and Teva Pharmaceuticals, and payments for organizing educational events from AstraZeneca, GlaxoSmithKline, Sanofi and Regeneron, and Teva Pharmaceuticals. Professor Pavord has received honoraria for attending advisory panels with AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Genentech, GlaxoSmithKline, Knopp, Novartis, Merck, Sanofi and Regeneron, and Teva Pharmaceuticals, and payments to support FDA approval meetings from GlaxoSmithKline. Professor Pavord has received sponsorship to attend international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Teva Pharmaceuticals. Professor Pavord has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. Professor Pavord is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Bayer, Insmed, and Merck. In 2014–5 he was an expert witness for a patent dispute involving AstraZeneca and Teva Pharmaceuticals.
Michael Wechsler
What Do We Know About Type 2 Inflammation in COPD?
Join Dr. Michael Wechsler as he discusses the significant burden of type 2 inflammation in COPD patients. Learn to recognize key indicators of type 2 inflammation, including elevated eosinophils.
Meet the expert
Michael Wechsler
Michael E. Wechsler, MD, MMSc, is Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at National Jewish Health (NJH) in Denver; Director of the NJH/Cohen Family Asthma Institute; and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary and critical care medicine, Dr. Wechsler’s research focuses on clinical and translational asthma with an emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis, (i.e. Churg-Strauss syndrome [CSS]).
Disclosures:
Dr. Wechsler has received consulting honoraria from AstraZeneca, Equillium, Gala Therapeutics, GlaxoSmithKline, Genzyme, Mylan, Pulmatrix, Regeneron, Restorbio, Sanofi, Sentien Biotechnologies, and Teva Pharmaceuticals.
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority in collaboration with Sanofi and Regeneron, with content provided by Sanofi and Regeneron. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-US-2405120 V1.0 – P Exp Date: 06/11/2026.
Sanofi and Regeneron are committed to providing resources to advance knowledge in areas of unmet medical need among patients with inflammatory and immunologic diseases.